4.6 Letter

Recommendations for phototherapy during the COVID-19 pandemic

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 83, Issue 1, Pages 287-288

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.04.091

Keywords

-

Categories

Funding

  1. Patient-Centered Outcomes Research Institute [PCS-1608-35830]

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Pharmacology & Pharmacy

Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis

Patrick O. Perche, Madison K. Cook, Steven R. Feldman

Summary: This article reviews the efficacy and safety of abrocitinib as an oral medication for patients with moderate-to-severe atopic dermatitis. The study found that abrocitinib is effective in treating atopic dermatitis, with higher efficacy compared to other conventional medications, and has fewer side effects.

ANNALS OF PHARMACOTHERAPY (2023)

Review Pharmacology & Pharmacy

Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis

Alexandra Taylor, Rohan Singh, Steven R. Feldman

Summary: This review highlights the pharmacokinetics, efficacy, and safety of recently approved calcipotriene and betamethasone dipropionate (C-BD) cream in the treatment of psoriasis. The results showed that C-BD cream was effective and safe, with higher treatment success rates compared to C-BD topical suspension and vehicle. The use of C-BD cream provides a convenient and preferred option for patients with mild-to-moderate psoriasis.

ANNALS OF PHARMACOTHERAPY (2023)

Review Pharmacology & Pharmacy

Review of Ruxolitinib in the Treatment of Atopic Dermatitis

Lindsey A. Mohney, Rohan Singh, Steven R. Feldman

Summary: This study reviews the pharmacokinetics, efficacy, and safety of a newly approved topical Janus kinase 1 (JAK) inhibitor, ruxolitinib (RUX), in patients with atopic dermatitis (AD). The results suggest that RUX is an effective and safe therapy for AD in adult patients.

ANNALS OF PHARMACOTHERAPY (2023)

Review Pharmacology & Pharmacy

Review of Tralokinumab in the Treatment of Atopic Dermatitis

Rohan Singh, Alexandra Taylor, Milaan A. Shah, Lindsay C. Strowd, Steven R. Feldman

Summary: This study reviewed the pharmacokinetics, efficacy, and safety of tralokinumab in the treatment of atopic dermatitis (AD). Data analysis demonstrated that tralokinumab is effective and safe as a monotherapy, in combination with topical corticosteroids (TCS), and in patients with resistance or contraindication to oral cyclosporine. Tralokinumab, which is associated with overexpression of IL-13, is an efficacious systemic treatment for moderate-to-severe AD.

ANNALS OF PHARMACOTHERAPY (2023)

Article Infectious Diseases

Prescribing Trends for Acne Vulgaris Visits in the United States

Patrick O. Perche, Gabrielle M. Peck, Lillian Robinson, Ayman Grada, Alan B. Fleischer Jr, Steven R. Feldman

Summary: Acne vulgaris is a common reason for patients to seek care from dermatologists in the US, but referring providers may be hesitant to prescribe acne treatments or certain medications. A study analyzed prescription rates for acne therapies from 1993 to 2016 and found that younger patients and privately insured patients were more likely to receive prescription treatments. Dermatologists were more likely to recommend prescription medications compared to family medicine and pediatric providers. Oral minocycline and oral doxycycline were the most commonly prescribed antibiotics, while benzoyl peroxide was the most utilized and recommended over-the-counter drug for acne.

ANTIBIOTICS-BASEL (2023)

Editorial Material Dermatology

Commentary on Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology

Heli Patel, Steven R. Feldman

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2023)

Review Pharmacology & Pharmacy

Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Christopher Alihosseini, Hannah Kopelman, Mallory Zaino, Steven R. Feldman

Summary: This study reviewed the safety and efficacy of avacopan for the treatment of ANCA-associated vasculitis. The results showed that avacopan can improve remission rates and reduce side effects caused by steroid use. Therefore, avacopan may be a new option for the treatment of ANCA-associated vasculitis.

ANNALS OF PHARMACOTHERAPY (2023)

Review Pharmacology & Pharmacy

A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis

Meghan C. Grossmann, Jessica N. Pixley, Steven R. Feldman

Summary: This article reviews the efficacy and safety of 1% tapinarof cream for plaque psoriasis. The results of two 12-week phase III clinical trials showed that around 35.4% to 40.2% of patients achieved clear or almost clear disease severity at week 12. In the 40-week, open-label extension trial, 40.9% of patients achieved a Physician's Global Assessment (PGA) score of 0 at least once. Tapinarof may be an effective and safe topical treatment for mild to severe plaque psoriasis.

ANNALS OF PHARMACOTHERAPY (2023)

Review Pharmacology & Pharmacy

A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex

Diem-Phuong D. Dao, Jessica N. Pixley, Zeynep M. Akkurt, Steven R. Feldman

Summary: This article evaluates the effectiveness, safety, pharmacology, and clinical applications of topical sirolimus 0.2% gel for treating tuberous sclerosis complex (TSC)-associated facial angiofibromas. The gel showed improvement in tumor size and redness without any serious adverse events. It is considered a safe and effective noninvasive alternative to surgical procedures for TSC-related angiofibromas.

ANNALS OF PHARMACOTHERAPY (2023)

Letter Dermatology

Facial analysis technologies do not appear to increase sunscreen use

Jessica N. Pixley, Mallory L. Zaino, Christina L. Kontzias, Rachel E. Tao, Steven R. Feldman

Summary: This study aimed to determine if showing patients their facial characteristics using an AI application would increase their use of sunscreen. The findings showed a decrease in self-reported sunscreen usage after the study, while skincare product usage remained unchanged.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)

Review Infectious Diseases

Oral Tetracycline-Class Drugs in Dermatology: Impact of Food Intake on Absorption and Efficacy

Rachel E. Tao, Stuti Prajapati, Jessica N. Pixley, Ayman Grada, Steven R. Feldman

Summary: Tetracycline-class drugs are commonly used in dermatology for treating skin diseases. This study reviewed the available evidence on whether taking these drugs with food affects their absorption and clinical efficacy. The study found that co-administration with food decreased systemic absorption of tetracycline, while the impact on doxycycline and minocycline varied. Oral sarecycline showed decreased absorption with food. Only sarecycline demonstrated limited or no impact of food intake on clinical efficacy. The study suggested considering patient adherence when choosing to take doxycycline, minocycline, and sarecycline with food.

ANTIBIOTICS-BASEL (2023)

Review Pharmacology & Pharmacy

Noncorticosteroid Topical Therapies for the Treatment of Plaque Psoriasis: A Narrative Review

Rithi J. J. Chandy, Diem-Phuong D. Dao, Cristian C. C. Rivis, Divya M. M. Shan, Steven R. R. Feldman

Summary: The objective of this study was to compare the safety and efficacy of noncorticosteroid topical treatments for plaque psoriasis. A literature search was conducted, and relevant articles and clinical trial data were analyzed. Six classes of noncorticosteroid topicals were studied, and the results showed that they are effective and safe for treating plaque psoriasis.

JOURNAL OF PHARMACY TECHNOLOGY (2023)

Review Biochemistry & Molecular Biology

The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options

Heli A. A. Patel, Rishab R. R. Revankar, Sofia T. T. Pedroza, Shaveonte Graham, Steven R. R. Feldman

Summary: Understanding the genetic factors in psoriasis can help improve targeted treatment strategies. This review discusses the genes associated with psoriasis pathogenesis and their connection to available treatment options. Searching various databases, relevant genetic markers and treatments were identified. Gene variants involved in inflammatory pathways, such as interleukins and interferons, are commonly implicated in psoriasis. Some treatments, like IL23 and TYK2 inhibitors, target genes associated with psoriasis. Multiple genes are involved in psoriasis pathogenesis, providing potential avenues for developing new treatment strategies and improving outcomes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Dermatology

Understanding the Medical Dictionary for Regulatory Activities (MedDRA) reporting of herpes simplex virus (HSV) adverse events in atopic dermatitis clinical trials

Rachel E. Tao, Jessica N. Pixley, Christina L. Kontzias, Steven R. Feldman

Summary: Drug efficacy is best evaluated through randomized, controlled, double-blind clinical trials, while safety assessment is more challenging. The Medical Dictionary for Regulatory Activities (MedDRA) is used to track and categorize adverse events (AE) during clinical trials. This study reviewed recent clinical trials on atopic dermatitis to demonstrate the importance of understanding MedDRA in evaluating adverse events related to herpes simplex virus (HSV) infection.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2023)

Review Dermatology

Quality of Life Assessments Utilized in Vitiligo Clinical Trials

Gaurav N. Pathak, Rithi J. Chandy, Vidisha Naini, Steven R. Feldman, Babar K. Rao

Summary: This study analyzed clinical trials on vitiligo and found that less than half of the trials used quality of life (QoL) assessments, with DLQI and CDLQI being the commonly used tools. As the number of trials increases, vitiligo-specific questionnaires may be more suitable for evaluating unique vitiligo-related concerns.

DERMATOLOGIC THERAPY (2023)

No Data Available